Items where authors include "Rudman, S."

Article

Culliford, R. orcid.org/0000-0003-4534-9241, Lawrence, S.E.D., Mills, C. orcid.org/0000-0002-4755-7549 et al. (40 more authors) (2024) Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma. Nature Communications, 15. 5935. ISSN 2041-1723

Motzer, R.J., Porta, C., Eto, M. et al. (238 more authors) (2024) Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology, 42 (11). pp. 1222-1228. ISSN 0732-183X

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

Arce Vargas, F., Furness, A.J.S., Litchfield, K. et al. (249 more authors) (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33 (4). 649-663.e4. ISSN 1535-6108